Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1041-1060 of 1,307 trials

Advanced Ovarian Cancer: Niraparib Alone vs. Niraparib with Bevacizumab

We are studying whether combining Niraparib with Bevacizumab improves outcomes for patients receiving chemotherapy for advanced ovarian cancer. This trial aims to see if the combination treatment helps patients live longer without their cancer progressing.

Ovarian CancerPeritoneal CarcinomaFallopian Tube CancerConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesOncology

Seizure Treatment After Cardiac Arrest: TELSTAR-2 Trial

We are studying whether a stepwise anti-seizure treatment helps improve outcomes for comatose patients who have seizures after cardiac arrest. This trial also looks at the healthcare costs associated with this treatment.

Cardiac ArrestComatoseStatus EpilepticusConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal MedicineNeurology

Ewing Sarcoma: Comparing Chemotherapy Treatments

We are studying different chemotherapy regimens for patients with recurrent or refractory Ewing Sarcoma. Our goal is to find the most effective and patient-friendly treatment option.

Ewing's Sarcoma3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer Imaging: 99mTc-MIP-1404 SPECT/CT Study

We are comparing a new imaging technique to standard methods for detecting prostate cancer spread in patients. This study aims to see if the new method improves detection of lymph node and bone metastases.

Prostate Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesOtolaryngologyUrology

Oropharyngeal Cancer: Comparing Treatment Options

We are studying different treatment regimens for patients with intermediate and high-risk oropharyngeal cancer to see if they improve survival and quality of life. This trial also aims to evaluate side effects and the cost-effectiveness of these treatments.

Oropharyngeal Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pediatric Hepatic Tumor Trial: Evaluating Treatments for Hepatoblastoma and Hepatocellular Carcinoma

We are studying different treatment approaches for children with liver tumors to see which may improve outcomes and reduce side effects. This trial also aims to collect samples for future research on these cancers.

Liver Cancer (Hepatoblastoma and Hepatocellular Carcinoma)≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHepatologyOncology

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin Study for Children

We are testing a new treatment combining gemtuzumab ozogamicin with standard chemotherapy for children with acute myeloid leukemia. The study aims to find the best dose and compare its effectiveness with current therapies.

Acute Myeloid LeukaemiaConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

ANCA-Vasculitis: Corticosteroid Dosing Study

We are investigating if taking corticosteroids twice daily helps patients with ANCA-vasculitis maintain better blood sugar levels. This study will measure glucose control using continuous monitoring.

ANCA-associated VasculitisRapid-Progressive Glomerulonephritis≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyRheumatology

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Immune Thrombocytopenia: Rituximab with Belimumab

We are studying whether adding belimumab to rituximab helps adults with persistent immune thrombocytopenia. This trial will compare the effects of the combination treatment to rituximab alone.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesHematology

Early Breast Cancer: Trastuzumab-Deruxtecan vs. Standard Care

We are studying a new treatment for early breast cancer patients who have had a molecular relapse. The trial aims to see if this new therapy clears cancer markers more effectively than standard treatments.

HER2-positive Breast CancerBreast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: S 95005 with Bevacizumab

We are studying a new treatment combination for patients with metastatic colorectal cancer who cannot receive intensive therapy. The goal is to see if it helps patients live longer without disease progression compared to standard treatment.

Metastatic Colorectal Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

High-Risk Breast Cancer: Personalized Chemotherapy Study

We are investigating a new chemotherapy treatment for patients with high-risk, HER2-negative breast cancer to see if it improves survival rates compared to standard therapies. This trial is for individuals with specific genetic profiles, including those without known BRCA mutations.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Psoriatic Arthritis: Sonelokimab Treatment Study

We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Psoriatic Arthritis: Sonelokimab Study

We are investigating the effects of sonelokimab in adults with active psoriatic arthritis who haven't responded to other treatments. This study compares sonelokimab to a placebo and an existing medication to see how well it works.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Hereditary Angioedema: Deucrictibant Extended-Release Tablet

We are studying a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The trial will evaluate its safety, effectiveness, and impact on quality of life.

Hereditary Angioedema>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Iron Deficiency Anemia in Children: Ferumoxytol Study

We are testing the safety and effectiveness of the drug ferumoxytol for children with iron deficiency anemia. This study compares it to an existing treatment to see how well it works.

Iron Deficiency Anemia≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyPediatrics